AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Wave Life Sciences Ltd. Director's Dealing 2016

Jul 13, 2016

31900_dirs_2016-07-13_0b1c010b-0fc4-4e10-9e02-6eedce77651f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2016-07-11

Reporting Person: Panzara Michael A. (Franchise Lead, Neurology)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-07-11	Ordinary Shares	A	22750	$0.00	Acquired	22750	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-07-11	Share Option (right to buy)	$21.69	A	150000	Acquired	2026-07-11	Ordinary Shares (150000)	Direct

Footnotes

F1: The option vests as to 25% of the shares on July 11, 2017 and vests as to an additional 2.0833% of the shares monthly thereafter until July 11, 2020.

F2: Consists of restricted stock units (RSUs). The RSUs vest as to 100% of the shares on July 11, 2017.